Compare Mesoblast Limited (MESO) vs TORM plc (TRMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs TORM plc — how do they compare? Mesoblast Limited trades at $16.38 (market cap $2.17B), while TORM plc trades at $29.89 (market cap $2.99B). The key difference: TORM plc is the larger of the two by market cap, and TORM plc pays a 9.62% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | TRMD | |
|---|---|---|
Market Cap | $2.17B | $2.99B |
Sector | Technology | Technology |
52-Week High | $20.96 | $34.87 |
52-Week Low | $12.88 | $17.50 |
Enterprise Value | $2.17B | $3.88B |
Dividend Yield | — | 9.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
TRMD trades at $29.08, up 2.21% today, with a neutral technical signal. The company reported strong profitability with a 24.41% net income margin and a low P/E of 8.34. Recent earnings showed a Q1 2026 miss but Q4 2025 beat, with Q2 2026 results pending. Cash flow from operations remains robust at $552 million in 2026, though net cash flow is negative. A $0.70 dividend for H1 2026 is scheduled, reflecting shareholder returns.
Outlook is positive due to strong fundamentals and 100% buy ratings from analysts, but risks include earnings volatility and negative net cash flow. The stock offers value with attractive valuation metrics and dividend yield, though investors should monitor Q2 earnings and cash flow trends for sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
